Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 12/20 | 0.71 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.71 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.59 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.59 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18096690 | 0.89 | GABRG2 (0.57) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL19922802 | 0.88 | GABRA3 (0.73) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL19922704 | 0.88 | GABRA3 (0.73) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL19922824 | 0.86 | GABRG2 (0.52) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL14217645 | 0.85 | GABRG2 (0.68) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL18105373 | 0.83 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL19929128 | 0.83 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL8360445 | 0.82 | GABRG2 (0.80) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL19922995 | 0.78 | GABRA3 (0.59) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL7721717 | 0.78 | GABRG2 (0.64) | GABRG2GABRB3GABRA3GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-10-08 | — | — | US | disclosed |
| US-20190300534-A1 | GABAERGIC LIGANDS AND THEIR USES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-10-03 | — | — | US | disclosed |
| US-10259815-B2 | Gabaergic ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10259815-B2 | Gabaergic ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180065967-A1 | GABAERGIC LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065967-A1 | GABAERGIC LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259815-B2 | Gabaergic ligands and their uses | GABRA3, GABRB3, GABRA2 | GABRG2 11/4885GABRB3 2/4885GABRA3 1/4885 |
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | GABRB2, GABRB1, GABRB3 | GABRG2 11/4885GABRB3 3/4885GABRA3 7/4885 |
| US-20190300534-A1 | GABAERGIC LIGANDS AND THEIR USES | GABRA3, GABRB3, GABRA2 | GABRG2 11/4885GABRB3 2/4885GABRA3 1/4885 |
| US-20180065967-A1 | GABAERGIC LIGANDS AND THEIR USES | GABRA3, GABRB3, GABRA2 | GABRG2 11/4885GABRB3 2/4885GABRA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.